Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigator Sponsored Research Proposal : Efficacy and Safety of Combination Ambrisentan and TadaLafil in PATiEnts With PortoPulmonary Hypertension (ESCALATE-PPH)

NCT03309592 is registered in ClinicalTrials.gov with Ochsner Health System as lead sponsor.

NCT NCT03309592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03309592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigator Sponsored Research Proposal : Efficacy and Safety of Combination Ambrisentan and TadaLafil in PATiEnts With PortoPulmonary Hypertension (ESCALATE-PPH)
Lead sponsor
Ochsner Health System
Phase
Phase 4
Overall status
Withdrawn
Start date
October 12, 2017
Completion date
November 1, 2018
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, liver, portopulmonary hypertension, pulmonary hypertension